New pill takes aim at Hard-to-Treat cancers with missing gene
NCT ID NCT06973863
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This early-stage trial is testing a new oral drug called PEP08 in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find a safe dose and see if the drug shows any signs of shrinking tumors, either alone or with other treatments. About 40 adults whose cancer has not responded to standard therapies will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
-
Westmead Hospital
RECRUITINGWentworthville, New South Wales, 2145, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PEP08 (an oral drug that targets a protein called PRMT5, which helps cancer cells grow)
What this could lead to
If successful, this could lead to a new treatment option for people with certain hard-to-treat cancers that have a specific genetic change (MTAP deletion).
What could go wrong
This is a very early (Phase 1) and small trial (40 people), so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects. It is too soon to know if it will work.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.